Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen Hirulog licensed to The Medicines Company for $30 mil..

Executive Summary

BIOGEN LICENSES HIRULOG TO THE MEDICINES COMPANY FOR $30 MIL. in upfront fees, milestone payments and development commitments, plus royalties on Hirulog sales, The Medicines Company announced March 25. Cambridge, Mass.-based TMC notes that its "deal structures are arranged to include royalties and milestone payments to the originating pharmaceutical company if market performance of a product exceeds the expectation of both parties." In return, TMC holds exclusive worldwide rights to develop and sell the synthetic leech protein derivative Hirulog (bivalirudin).

You may also be interested in...



It Has Been A Long Farewell To The Medicines Company

The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.

TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force

The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.

TMC Angiomax Launch Projected For Mid-2001 With Innovex Sales Force

The Medicines Company expects to launch its anticoagulant Angiomax (bivalirudin) by mid-2001 with the help of Quintiles' contract sales division Innovex.

Latest News
See All
UsernamePublicRestriction

Register

PS029933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel